Phase 2 Rare Disease Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who are able to understand the study and sign a written consent form.
• People who have been confirmed through biopsy or lab testing to have one of the following cancers: Paget's disease of the scrotum with sweat gland cancer, rhabdomyosarcoma, testicular cancer, penile cancer, or urachal cancer.
• People whose cancer has reached Stage IV (advanced/spread).
• People who are reasonably active and able to care for themselves (as assessed by a doctor using a standard scale).
• People whose life expectancy is at least 3 months.
• People whose cancer can be measured on a CT or MRI scan, or who have cancer that has visibly affected the skin.
• People whose blood counts are at an acceptable level without needing regular blood transfusions (specific blood count thresholds apply).
• People whose kidneys and liver are functioning at an acceptable level (confirmed through blood tests).
• People whose blood clotting function is within an acceptable range (confirmed through blood tests).
• People who are willing to use an approved form of contraception from enrollment until at least 120 days after the study ends, and who agree not to donate sperm or store sperm for reproduction during this period.
• People who are able to attend required study visits and follow the study schedule.

Who may not be able to join:

• People who have a serious active infection that is not under control and requires treatment with antibiotics, antifungal, or antiviral medicines, including active tuberculosis.
• People with active hepatitis B or C at levels above certain thresholds (people receiving antiviral treatment that has brought levels below those thresholds may still be considered — confirm with trial site).
• People whose kidneys have failed to the point of requiring dialysis.
• People with a history of immune system problems, including HIV, other immune deficiency conditions, or a history of organ transplant.
• People experiencing severe ongoing symptoms such as nausea, headaches, insomnia, fatigue, excessive sleepiness, dry mouth, dizziness, or constipation.
• People with a history of active tuberculosis.
• People who have uncontrolled fluid build-up in the abdomen, around the lungs, or around the heart that requires repeated draining.
• People who have had a major organ transplant.
• People who have had major surgery, an open biopsy, or a significant injury within the 28 days before the study starts, or who have wounds or fractures that have not healed.
• People who have taken part in another clinical trial within the past 4 weeks before the study starts.
• People who have a history of severe allergic reactions.
• People who are at risk of bleeding, have a blood clotting problem, or are currently receiving blood clot-dissolving therapy.
• People with a history of substance abuse who are unable to stop using, or who have a mental health disorder.
• People with a clearly diagnosed neurological or psychiatric condition, such as dementia or epilepsy, or a history that puts them at risk of seizures.
• People who, in the treating doctor's judgment, have other conditions or circumstances that could put their safety at risk or prevent them from completing the study.

Important: Always verify eligibility with the trial site directly before applying.